Highlights

  • ALS reported record FY26 revenue of $3.32 billion, up 10.7%, while underlying NPAT increased 25.8% to $381.2 million.
  • The company delivered significant margin expansion across key divisions, supported by increased mineral exploration activity and operational leverage.
  • Management is targeting mid-to-high single-digit organic revenue growth in FY27, with further margin improvement expected across the business.

ALS Ltd (ASX:ALQ) attracted investor attention following the release of its FY26 results, with shares rising 4.26% on 15 June 2026 to close at AUD 23.50.

Adding to market optimism, Bell Potter maintained a Buy rating on the stock with a target price of AUD 26.00.

The latest financial year represented one of ALS's most successful reporting periods, with revenue, profitability, cash generation, and shareholder returns all moving higher.

For investors evaluating the stock, the central question is whether the company's earnings momentum and operational execution can continue into FY27.

Record Revenue and Profit Growth Highlight Operational Performance

ALS delivered revenue of $3.32 billion during FY26, representing growth of 10.7% compared with the previous year.

The result was largely driven by strong organic growth within the Commodities division, which benefited from increased mineral exploration activity globally. While growth within Life Sciences was more mixed across different regions and markets, overall group performance remained favourable.

Underlying EBIT increased 19.3% to $599.0 million, significantly outpacing revenue growth. This translated into an underlying EBIT margin of 18.0%, representing an improvement of 129 basis points compared with FY25.

Underlying net profit after tax reached $381.2 million, increasing 25.8% year over year. Statutory NPAT also rose 24.4% to $318.7 million.

The earnings growth was supported by a combination of operational leverage, favourable foreign exchange impacts during the first half, lower financing costs following the May 2025 equity raising, and continued demand across mineral testing services.

The gap between revenue growth and profit growth demonstrates how operating efficiencies and margin expansion contributed to earnings performance during the year.

Commodities Division Continues to Lead Growth

The Commodities segment remained the key earnings driver for ALS during FY26.

Within the Minerals business, margins expanded further to 33.0%, reflecting increasing sample volumes and pricing improvements, particularly during the second half of the financial year.

Management noted that the ongoing cyclical improvement in global mineral exploration activity continued to support testing demand across major mining jurisdictions. This trend has been beneficial for ALS, which operates one of the world's largest independent laboratory testing networks serving mining and exploration clients.

The company's outlook for FY27 remains particularly optimistic for this segment. ALS expects Minerals revenue growth of between 13% and 15% organically during FY27, with management expressing greater confidence regarding 15% to 17% organic growth during the first half of the year.

Margins are also expected to remain near current levels, with a further 30 to 50 basis points of improvement anticipated in the second half of FY27.

For investors, this segment remains central to the company's growth narrative.

Life Sciences Delivers Mixed Regional Performance

While Commodities generated most of the earnings momentum, Life Sciences delivered a more varied performance.

Environmental testing operations faced softer trading conditions during the second half, particularly in the Americas. Management attributed this to a combination of internal quality and cost challenges, alongside external market factors and project delays linked to the US government shutdown during the third quarter.

Despite these headwinds, ALS reported that its major operations across Asia-Pacific and Europe, the Middle East and Africa continued to perform positively, generating mid-single-digit revenue growth.

The company has initiated remediation efforts to address operational issues within affected regions, and management appears focused on restoring growth momentum within the Environmental division.

Investors will likely monitor whether these corrective actions translate into improved performance over the coming year.

Cash Flow and Balance Sheet Provide Financial Flexibility

One of the most notable aspects of the FY26 result was ALS's cash generation capability.

Free cash flow reached $674.1 million during the year, while EBITDA cash conversion stood at 92%. These metrics highlight the company's ability to translate earnings into cash, supporting both shareholder returns and future investment opportunities.

Financial leverage declined to 1.5 times following the FY25 equity raising and continued cash generation. This level sits below the company's targeted leverage range of 1.7 to 2.3 times.

Additionally, ALS reported available liquidity exceeding $580 million, providing significant financial flexibility.

A stronger balance sheet allows the company to continue investing in organic growth projects while maintaining the capacity to pursue acquisitions when opportunities arise.

In the testing and inspection industry, financial flexibility can be particularly important because acquisitions often play a role in expanding geographic reach and technical capabilities.

Growth Investments Enter a New Phase

ALS continues to invest heavily in future growth initiatives.

Several laboratory hub projects remain on schedule and within budget, including facilities in Sydney and Lima that are expected to become operational during the second half of FY27.

The company's "Lab of the Future" initiative is also progressing from its investment stage into early implementation.

Management expects FY27 to mark the beginning of tangible benefits from investments in laboratory automation, digital infrastructure, and artificial intelligence capabilities. While the impact is expected to be relatively modest initially, the company anticipates more meaningful operational benefits over subsequent years.

These initiatives are designed to improve efficiency, enhance productivity, and support scalability as testing volumes increase.

For long-term investors, the ability to leverage technology across a global laboratory network could become an increasingly important competitive factor.

Dividend Growth Reflects Earnings Improvement

ALS also rewarded shareholders with higher dividend payments following its record result.

The board declared a final dividend of 23.1 cents per share, partially franked at 30%, representing an increase from the prior year's final dividend of 19.7 cents per share.

Combined with the interim dividend, total FY26 dividends reached 42.5 cents per share, up 10.1% from FY25.

The payout ratio of approximately 57% reflects management's balanced approach between returning capital to shareholders and retaining funds to support growth investments.

The dividend increase provides further evidence of management's confidence in the company's cash generation and earnings outlook.

FY27 Outlook Remains Positive Despite External Risks

Looking ahead, ALS is targeting mid-to-high single-digit organic revenue growth at the group level while pursuing margin expansion similar to the improvements achieved during FY26.

Management acknowledged ongoing geopolitical uncertainty and potential foreign exchange headwinds. The company also identified supply chain risks associated with Middle Eastern conflict, although procurement strategies are expected to limit financial impacts.

Foreign exchange movements may create earnings pressure during FY27, with management estimating that each 1% movement in major currency rates versus the Australian dollar could reduce annual underlying EBIT by approximately $3 million.

Despite these challenges, ALS continues to project favourable growth across its key business segments, particularly within Minerals and Industrial Materials.

Is ALS Stock a Buy, Hold or Sell Opportunity?

ALS enters FY27 following a record financial year characterized by double-digit revenue growth, accelerating profit expansion, improving margins, substantial cash generation, and rising dividends. The company remains positively exposed to mineral exploration activity, while investments in automation, digital infrastructure, and laboratory capacity create additional growth avenues beyond the current cycle.

Although risks remain from foreign exchange movements, geopolitical uncertainty, and uneven conditions within parts of the Environmental business, management's guidance suggests confidence in sustaining growth momentum. Following the latest earnings release, ALS appears to be a stock many investors may consider keeping on their watchlist, particularly given its exposure to long-term resource exploration trends, improving profitability profile, and financial flexibility to support future expansion.

FAQs

Q: What were ALS's key FY26 financial results?
A: ALS reported revenue of $3.32 billion, up 10.7%, while underlying NPAT increased 25.8% to $381.2 million.

Q: Why did ALS's profit grow faster than revenue?
A: Profit growth benefited from margin expansion, operating leverage, favourable foreign exchange impacts during the first half, and lower interest expenses.

Q: What is driving growth in ALS's Commodities division?
A: Increased global mineral exploration activity, higher sample volumes, and improved pricing have supported growth in the Minerals testing business.

Q: What is the outlook for ALS in FY27?
A: Management expects mid-to-high single-digit organic revenue growth across the group, with further margin expansion and continued strength in Minerals.

Q: Did ALS increase its dividend?
A: Yes. Total FY26 dividends increased 10.1% to 42.5 cents per share, reflecting higher earnings and strong cash generation.